Cerebrovascular P-glycoprotein expression is decreased in Creutzfeldt-Jakob disease

Acta Neuropathologica

Volumn 111, Issue 5, 2006, Pages 436-443

  Vogelgesang, Silke ^a   Glatzel, Markus ^b   Walker, Lary C ^c   Kroemer, Heyo K ^a   Aguzzi, Adriano ^d   Warzok, Rolf W ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

amyloid; Alzheimer's disease; Cerebral amyloid angiopathy; Creutzfeldt Jakob disease; P glycoprotein; Prion; Proteopathies

Indexed keywords

AMYLOID BETA PROTEIN; GLYCOPROTEIN P; PRION PROTEIN; PROTEASOME; TAU PROTEIN; UBIQUITIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABORATORY DIAGNOSIS; MALE; MOLECULAR MECHANICS; OCCIPITAL LOBE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TEMPORAL LOBE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CEREBRAL AMYLOID ANGIOPATHY; CEREBRAL ARTERIES; CREUTZFELDT-JAKOB SYNDROME; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PRION DISEASES;

EID: 33646241523     PISSN: 00016322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00401-006-0042-3     Document Type: Article

References (52)

1. Abbott NJ, Khan EU, Rollinson CM, Reichel A, Janigro D, Dombrowski SM, Dobbie MS, Begley DJ (2002) Drug resistance in epilepsy: The role of the blood-brain barrier. Novartis Found Symp 243:38-47
2. Aguzzi A, Haass C (2003) Games played by rogue proteins in prion disorders and Alzheimer's disease. Science 302:814-818
3. Armstrong RA, Lantos PL, Cairns NJ (2001) The spatial patterns of prion protein deposits in Creutzfeldt-Jakob disease: Comparison with beta-amyloid deposits in Alzheimer's disease. Neurosci Lett 298:53-56
4. Begley GS, Horvath AR, Taylor JC, Higgins CF (2005) Cytoplasmic domains of the transporter associated with antigen processing and P-glycoprotein interact with subunits of the proteasome. Mol Immunol 42:137-141
5. Budka H (2003) Neuropathology of prion diseases. Br Med Bull 66:121-130
6. Carrell RW, Lomas DA (1997) Conformational disease. Lancet 350:134-138
7. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I (2001) Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69:169-174
8. Chapman J, Cervenakova L, Petersen RB, Lee HS, Estupinan J, Richardson S, Vnencak-Jones CL, Gajdusek DC, Korczyn AD, Brown P, Goldfarb LG (1998) APOE in non-Alzheimer amyloidoses: Transmissible spongiform encephalopathies. Neurology 51:548-553
9. Chiti F, Calamai M, Taddei N, Stefani M, Ramponi G, Dobson CM (2002) Studies of the aggregation of mutant proteins in vitro provide insights into the genetics of amyloid diseases. Proc Natl Acad Sci USA 99(Suppl 4):16419-16426
10. Ciechanover A, Brundin P (2003) The ubiquitin proteasome system in neurodegenerative diseases: Sometimes the chicken, sometimes the egg. Neuron 40:427-446
11. Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, Jiang H, Prior JL, Sagare A, Bales KR, Paul SM, Zlokovic BV, Piwnica-Worms D, Holtzman DM (2005) P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest 115:3285-3290
12. Collinge J (1998) Human prion diseases: Aetiology and clinical features. In: Growdon JH, Rossor M, Newton MA (eds) The dementias. Butterworth-Heinemann, Oxford, pp 113-148
13. Deane R, Wu Z, Zlokovic BV (2004) RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke 35(Suppl 1):2628-2631
14. DeArmond SJ, Prusiner SB (1995) Etiology and pathogenesis of prion diseases. Am J Pathol 146:785-811
15. Demeule M, Regina A, Jodoin J, Laplante A, Dagenais C, Berthelet F, Moghrabi A, Beliveau R (2002) Drug transport to the brain: Key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vascul Pharmacol 38:339-348
16. Drozdzik M, Bialecka M, Mysliwiec K, Honczarenko K, Stankiewicz J, Sych Z (2003) Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics 13:259-263
17. Fromm MF, Kauffmann HM, Fritz P, Burk O, Kroemer HK, Warzok RW, Eichelbaum M, Siegmund W, Schrenk D (2000) The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol 157:1575-1580
18. Fromm MF (2004) Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 25:423-429
19. Furuno T, Landi MT, Ceroni M, Caporaso N, Bernucci I, Nappi G, Martignoni E, Schaeffeler E, Eichelbaum M, Schwab M, Zanger UM (2002) Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. Pharmacogenetics 12:529-534
20. Glatzel M, Rogivue C, Ghani A, Streffer JR, Amsler L, Aguzzi A (2002) Incidence of Creutzfeldt-Jakob disease in Switzerland. Lancet 360:139-141
21. Hainfellner JA, Wanschitz J, Jellinger K, Liberski PP, Gullotta F, Budka H (1998) Coexistence of Alzheimer-type neuropathology in Creutzfeldt-Jakob disease. Acta Neuropathol 96:116-122
22. Hardy J (2005) Expression of normal sequence pathogenic proteins for neurodegenerative disease contributes to disease risk: Permissive templating as a general mechanism underlying neurodegeneration. Biochem Soc Trans 33:578-581
23. Hennessy M, Kelleher D, Spiers JP, Barry M, Kavanagh P, Back D, Mulcahy F, Feely J (2002) St Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol 53:75-82
24. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473-3478
25. Kakizuka A (1998) Protein precipitation: A common etiology in neurodegenerative disorders? Trends Genet 14:396-402
26. Koo EH, Lansbury PT Jr, Kelly JW (1999) Amyloid diseases: Abnormal protein aggregation in neurodegeneration. Proc Natl Acad Sci USA 96:9989-9990
27. Kovacs GG, Budka H (2002) Aging, the brain and human prion disease. Exp Gerontol 37:603-605
28. Lam FC, Liu R, Lu P, Shapiro AB, Renoir JM, Sharom FJ, Reiner PB (2001) beta-Amyloid efflux mediated by P-glycoprotein. J Neurochem 76:1121-1128
29. Lopez Salon M, Pasquini L, Besio Moreno M, Pasquini JM, Soto E (2003) Relationship between beta-amyloid degradation and the 26S proteasome in neural cells. Exp Neurol 180:131-143
30. Ma J, Lindquist S (2002) Conversion of PrP to a self-perpetuating PrPSc-like conformation in the cytosol. Science 298:1785-1788
31. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM (2004) Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43:321-332
32. Otto M, Esselmann H, Schulz-Shaeffer W, Neumann M, Schroter A, Ratzka P, Cepek L, Zerr I, Steinacker P, Windl O, Kornhuber J, Kretzschmar HA, Poser S, Wiltfang J (2000) Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology 54:1099-1102
33. Parchi P, Giese A, Capellari S, Brown P, Schulz-Schaeffer W, Windl O, Zerr I, Budka H, Kopp N, Piccardo P, Poser S, Rojiani A, Streichemberger N, Julien J, Vital C, Ghetti B, Gambetti P, Kretzschmar H (1999) Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 46:224-233
34. Petrucelli L, Dawson TM (2004) Mechanism of neurodegenerative disease: role of the ubiquitin proteasome system. Ann Med 36:315-320
35. Rane NS, Yonkovich JL, Hegde RS (2004) Protection from cytosolic prion protein toxicity by modulation of protein translocation. EMBO J 23:4550-4559
36. Revesz T, Ghiso J, Lashley T, Plant G, Rostagno A, Frangione B, Holton JL (2003) Cerebral amyloid angiopathies: A pathologic, biochemical, and genetic view. J Neuropathol Exp Neurol 62:885-898
37. Schinkel AH, Jonker JW (2003) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: An overview. Adv Drug Deliv Rev 55:3-29
38. Schwab M, Eichelbaum M, Fromm MF (2003) Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol 43:285-307
39. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV. (2000) Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106:1489-1499
40. Smyth MJ, Krasovskis E, Sutton VR, Johnstone RW (1998) The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci USA 95:7024-7029
41. Tainton KM, Smyth MJ, Jackson JT, Tanner JE, Cerruti L, Jane SM, Darcy PK, Johnstone RW (2004) Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux. Cell Death Differ 11:1028-1037
42. Terasaki T, Ohtsuki S (2005) Brain-to-blood transporters for endogenous substrates and xenobiotics at the blood-brain barrier: An overview of biology and methodology. NeuroRx 2:63-72
43. Unterberger U, Voigtlander T, Budka H (2005) Pathogenesis of prion diseases. Acta Neuropathol 109:32-48
44. Vogelgesang S, Cascorbi I, Schroeder E, Pahnke J, Kroemer HK, Siegmund W, Kunert-Keil C, Walker LC, Warzok RW (2002) Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 12:535-541
45. Vogelgesang S, Warzok RW, Cascorbi I, Kunert-Keil C, Schroeder E, Kroemer HK, Siegmund W, Walker LC, Pahnke J (2004) The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease. Curr Alzheimer Res 1:121-125
46. Walker LC, LeVine H (2000) The cerebral proteopathies: Neurodegenerative disorders of protein conformation and assembly. Mol Neurobiol 21:83-95
47. Walker LC, Pahnke J, Madauss M, Vogelgesang S, Pahnke A, Herbst EW, Stausske D, Walther R, Kessler C, Warzok RW (2000) Apolipoprotein E4 promotes the early deposition of Abeta42 and then Abeta40 in the elderly. Acta Neuropathol 100:36-42
48. Walker LC, LeVine H III (2002) Proteopathy: The next therapeutic frontier? Curr Opin Investig Drugs 3:782-787
49. Warzok RW, Kessler C, Apel G, Schwarz A, Egensperger R, Schreiber D, Herbst EW, Wolf E, Walther R, Walker LC (1998) Apolipoprotein E4 promotes incipient Alzheimer pathology in the elderly. Alzheimer Dis Assoc Disord 12:33-39
50. Wiltfang J, Esselmann H, Smirnov A, Bibl M, Cepek L, Steinacker P, Mollenhauer B, Buerger K, Hampel H, Paul S, Neumann M, Maler M, Zerr I, Kornhuber J, Kretzschmar HA, Poser S, Otto M (2003) Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Ann Neurol 54:263-267
51. Yang ZY, Liu GQ (2004) Effect of P-glycoprotein inhibitor combinations on drug efflux from rat brain microvessel endothelial cells. Pharmazie 59:952-956
52. Yedidia Y, Horonchik L, Tzaban S, Yanai A, Taraboulos A (2001) Proteasomes and ubiquitin are involved in the turnover of the wild-type prion protein. EMBO J 20:5383-5391